Preferred Label : Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein;
NCIt synonyms : Recombinant Anti-CD20 B9E9 scFvSA Fusion Protein; Anti-CD20 B9E9-SA Fusion Protein; scFv B9E9-streptavidin Fusion Protein; B9E9 scFvSA Fusion Protein; Anti-CD20 B9E9 scFv-SA Fusion Protein;
NCIt definition : An Escherichia coli periplasm-expressed tetrameric fusion protein composed of four
single-chain variable regions (scFv) of the murine immunoglobulin (Ig) G2a anti-CD20
monoclonal antibody B9E9 fused to the streptavidin (SA) gene of Streptomyces avidinii
(scFv-SA), with potential use in pretargeted radioimmunotherapy (PRIT). Upon intravenous
administration of the anti-CD20 B9E9 scFv-SA fusion protein, this agent targets and
binds to CD20-expressing tumor cells. Subsequently, a biotinylated N-acetylgalactosamine-containing
clearing agent is administered, which binds to the streptavidin moiety of the unbound
fusion protein and promotes its hepatic excretion. In turn, radiolabeled DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
acid)-biotin is administered and, due to its small size, quickly distributes. The
biotin moiety efficiently binds to the SA moiety of the bound fusion protein, which
localizes the biotin-conjugated radionuclide to the tumor site. CD20, a tumor-associated
antigen (TAA), is overexpressed on B-cell malignancies. PRIT increases both tumor
uptake and renal elimination of the radionuclide conjugate as compared to conventional
radioimmunotherapy (RIT), where the radioisotope is bound to the antibody before administration;
this increases the dose of radionuclide delivered to the tumor while limiting radiation
exposure for normal, healthy tissues.;
Origin ID : C121167;
UMLS CUI : C4055461;
Semantic type(s)
- concept_is_in_subset
- has_target
